The lawyer for former spokesperson Phoebe Jonas said Bayer created "a big headache for everyone."
Medical science liaisons are essential participants in most aspects of the commercialization process.
MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.
MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.
Botox Cosmetic has rolled out its first ad campaign focused on reaching male customers.
Thanks to legalization, a new breed of startups are changing the nature of cannabis advertising.
Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
Dr. Jessica Grossman is CEO of Medicines360.
The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?
Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
He was diagnosed years ago with a handful of autoimmune conditions, treating them with drugs like Abbvie's Humira, which he helped commercialize.
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
What's holding back value-based pricing deals from moving beyond the pilot phase?
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
AbbVie's new HCV drug is cheaper than Gilead's Harvoni; Lilly's experimental migraine drugs beats placebo; Fitbit to launch smartwatch
The drugmaker is one step closer to a potential approval of its experimental cancer treatment.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
Medicare beneficiaries struggle to pay for COPD inhalers; Novartis partners with IBM Watson Health; Mylan hasn't lowered EpiPen prices
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.